Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orphan Drug Status: Are Head-to-head Trials Needed To Show Superior Safety?

This article was originally published in The Pink Sheet Daily

Executive Summary

CSL Behring petitions FDA to revoke Wilate's orphan drug designation, but Octapharma counters that the effectiveness of its product's dual viral inactivation processes can be seen in post-market reporting.

You may also be interested in...

Plausibility Takes A Hit: FDA Revokes Orphan Exclusivity For Octapharma’s Wilate

In the first-ever rescission of marketing exclusivity for an orphan drug, FDA concludes that data does not show Wilate is superior to CSL Behring’s Factor VIII drug Humate-P. Wilate had previously been awarded orphan drug exclusivity for the same indication because of a “plausible hypothesis” that it was safer.

Serono Rebif Blocked By Orphan Exclusivity, FDA Says, But Timing Is Unclear

Serono has been informed by FDA that approval of its multiple sclerosis therapy Rebif is blocked by the orphan drug exclusivity of both Berlex' Betaseron and Biogen's Avonex, but has not been given a date for when that exclusivity will expire.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts